BROADENING OF GENERALIZED ANXIETY DISORDERS DEFINITION DOES NOT AFFECT THE RESPONSE TO THERAPY: FINDINGS FROM THE ADAN STUDY

E. Álvarez1, J.L. Carrasco2, J.M. Olivares3, M. Perez4, V. Pérez-Gómez4, I. Vilardaga5, J. Rejas6

1Department of Psychiatry, Hospital de la Santa Creu i San Pau, Barcelona, 2Department of Psychiatry, Hospital Clínico San Carlos, Madrid, 3Department of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo, 4Department of Neuroscience, Medical Unit, Pfizer Spain, Alcobendas (Madrid), 5Department of Biometric and Statistic, European Biometric Institute, Barcelona, 6Health Outcomes Research Department, Medical Unit, Pfizer Spain, Alcobendas (Madrid), Spain

Purpose: To elucidate the consequences of broadening DSM-IV criteria for generalized anxiety disorder (GAD), we examined the evolution of GAD symptoms in two groups of newly diagnosed patients; one group according to DSM-IV criteria and the other, according to broader criteria.

Methods: Multicentre, prospective and observational study conducted in outpatient psychiatric clinics. Patients with GAD according to DSM-IV criteria and subjects with anxiety symptoms fulfilling broader criteria were compared. Broadening criteria was considered 1-month of excessive or non-excessive worry and only 2 associated symptoms listed on DSM-IV for GAD. Socio-demographic data, medical history and functional outcome measures were collected three times during a 6-month period.

Results: 3,549 patients were systematically recruited; 12.8% excluded because not fulfilling inclusion criteria, 1,815 patients in DSM-IV group (DG) and 1,264 in broad group (BG). Both groups were similar on their sociodemographic characteristics at baseline and most patients (about 80%), even newly diagnosed were exposed previously to pharmaceutical therapies (mainly benzodiazepines) of their anxiety symptoms. As a result of treatment at psychiatric clinics, the percentage of patients without symptoms of anxiety as per HAM-A scale were 49.0% and 58.0%, respectively at the 6 month visit (p=0.261). Similarly, responder rate (≥ 50% reduction of baseline scoring) were, respectively, 59.7% and 67.7% (p=0.103). Improvement in MADRS scores were observed in both group to a similar extent; 12.1 and 12.5 points average reduction respectively (p=0.264).

Conclusion: Broadening of GAD criteria could lead to earlier diagnosis that will benefit patients by starting appropriate treatment sooner.